BTAI BioXcel Therapeutics Inc
Price (delayed)
$0.667
Market cap
$27.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.55
Enterprise value
$74.17M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
Highlights
The gross profit has soared by 144% from the previous quarter and by 5% YoY
BTAI's revenue has surged by 132% year-on-year and by 37% since the previous quarter
BTAI's gross margin has surged by 79% since the previous quarter but it has dropped by 54% year-on-year
BTAI's quick ratio is down by 43% year-on-year and by 12% since the previous quarter
BTAI's debt is up by 6% year-on-year
Key stats
What are the main financial stats of BTAI
Market
Valuations
Earnings
Shares outstanding
40.74M
Market cap
$27.18M
Enterprise value
$74.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.86
Revenue
$2.4M
EBIT
-$93.84M
EBITDA
-$93.53M
Free cash flow
-$105.33M
Per share
Balance sheet
Liquidity
EPS
-$3.55
Free cash flow per share
-$2.62
Book value per share
-$1.98
Revenue per share
$0.06
TBVPS
$1.63
Total assets
$65.44M
Total liabilities
$139.74M
Debt
$103.26M
Equity
-$74.3M
Working capital
$36.89M
Debt to equity
-1.39
Current ratio
2.35
Quick ratio
2.09
Net debt/EBITDA
-0.5
Margins
Efficiency
Dividend
EBITDA margin
-3,892.1%
Gross margin
43.1%
Net margin
-4,487.4%
Operating margin
-4,562.3%
Return on assets
-134%
Return on equity
N/A
Return on invested capital
-118.5%
Return on capital employed
-246%
Return on sales
-3,905%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BTAI stock price
How has the BioXcel Therapeutics stock price performed over time
Intraday
-1.91%
1 week
20.46%
1 month
-0.92%
1 year
-80.03%
YTD
-77.39%
QTD
-47.89%
Financial performance
How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$2.4M
Gross profit
$1.04M
Operating income
-$109.63M
Net income
-$107.83M
Gross margin
43.1%
Net margin
-4,487.4%
The gross profit has soared by 144% from the previous quarter and by 5% YoY
BTAI's revenue has surged by 132% year-on-year and by 37% since the previous quarter
BTAI's gross margin has surged by 79% since the previous quarter but it has dropped by 54% year-on-year
BTAI's net margin has surged by 77% year-on-year and by 49% since the previous quarter
Growth
What is BioXcel Therapeutics's growth rate over time
Valuation
What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
11.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.86
BTAI's EPS has surged by 50% year-on-year and by 31% since the previous quarter
The equity has declined by 2.7% since the previous quarter
BTAI's revenue has surged by 132% year-on-year and by 37% since the previous quarter
The price to sales (P/S) is 76% lower than the last 4 quarters average of 48.2
Efficiency
How efficient is BioXcel Therapeutics business performance
BTAI's return on sales has surged by 79% year-on-year and by 51% since the previous quarter
BioXcel Therapeutics's ROIC has soared by 51% YoY and by 35% from the previous quarter
BioXcel Therapeutics's return on assets has decreased by 27% YoY but it has increased by 13% QoQ
Dividends
What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BTAI.
Financial health
How did BioXcel Therapeutics financials performed over time
The total assets is 53% less than the total liabilities
The total assets has plunged by 53% YoY and by 21% from the previous quarter
BTAI's quick ratio is down by 43% year-on-year and by 12% since the previous quarter
BioXcel Therapeutics's debt to equity has plunged by 108% YoY
BTAI's debt is up by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.